Trade Organovo Holdings, Inc. - ONVO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.11 |
Open* | 2.14 |
1-Year Change* | -43.09% |
Day's Range* | 2.13 - 2.21 |
52 wk Range | 1.37-3.79 |
Average Volume (10 days) | 34.56K |
Average Volume (3 months) | 2.52M |
Market Cap | 19.08M |
P/E Ratio | -100.00K |
Shares Outstanding | 8.71M |
Revenue | 1.71M |
EPS | -1.34 |
Dividend (Yield %) | N/A |
Beta | 0.88 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 2.17 | 0.04 | 1.88% | 2.13 | 2.21 | 2.13 |
Mar 30, 2023 | 2.11 | -0.11 | -4.95% | 2.22 | 2.26 | 2.01 |
Mar 29, 2023 | 2.24 | 0.12 | 5.66% | 2.12 | 2.24 | 2.04 |
Mar 28, 2023 | 2.17 | -0.07 | -3.13% | 2.24 | 2.30 | 2.12 |
Mar 27, 2023 | 2.22 | 0.19 | 9.36% | 2.03 | 2.27 | 2.00 |
Mar 24, 2023 | 1.98 | 0.07 | 3.66% | 1.91 | 1.98 | 1.91 |
Mar 23, 2023 | 1.93 | -0.10 | -4.93% | 2.03 | 2.06 | 1.91 |
Mar 22, 2023 | 1.99 | 0.06 | 3.11% | 1.93 | 2.03 | 1.91 |
Mar 21, 2023 | 1.91 | 0.03 | 1.60% | 1.88 | 1.96 | 1.88 |
Mar 20, 2023 | 1.88 | -0.08 | -4.08% | 1.96 | 1.97 | 1.84 |
Mar 17, 2023 | 1.93 | 0.04 | 2.12% | 1.89 | 1.97 | 1.88 |
Mar 16, 2023 | 1.94 | 0.05 | 2.65% | 1.89 | 1.98 | 1.88 |
Mar 15, 2023 | 1.89 | 0.01 | 0.53% | 1.88 | 1.93 | 1.87 |
Mar 14, 2023 | 1.94 | 0.05 | 2.65% | 1.89 | 1.99 | 1.85 |
Mar 13, 2023 | 1.87 | 0.14 | 8.09% | 1.73 | 1.94 | 1.71 |
Mar 10, 2023 | 1.78 | -0.08 | -4.30% | 1.86 | 1.86 | 1.74 |
Mar 9, 2023 | 1.85 | -0.18 | -8.87% | 2.03 | 2.04 | 1.83 |
Mar 8, 2023 | 2.05 | -0.07 | -3.30% | 2.12 | 2.12 | 2.02 |
Mar 7, 2023 | 2.10 | -0.08 | -3.67% | 2.18 | 2.19 | 2.03 |
Mar 6, 2023 | 2.21 | 0.03 | 1.38% | 2.18 | 2.23 | 2.17 |
Organovo Holdings, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1.5 | 0 | 2.196 | 3.091 | 4.603 |
Revenue | 1.5 | 0 | 2.196 | 3.091 | 4.603 |
Cost of Revenue, Total | 0 | 0.328 | 0.482 | 1.03 | |
Gross Profit | 0 | 1.868 | 2.609 | 3.573 | |
Total Operating Expense | 12.979 | 16.826 | 23.671 | 30.365 | 39.874 |
Selling/General/Admin. Expenses, Total | 9.631 | 12.9 | 14.423 | 15.131 | 20.888 |
Research & Development | 3.206 | 1.077 | 5.051 | 14.752 | 17.956 |
Operating Income | -11.479 | -16.826 | -21.475 | -27.274 | -35.271 |
Interest Income (Expense), Net Non-Operating | 0.008 | 0.015 | 0.594 | 0.705 | 0.478 |
Gain (Loss) on Sale of Assets | 0 | -0.019 | 0.113 | -0.063 | 0.004 |
Net Income Before Taxes | -11.446 | -16.824 | -18.708 | -26.632 | -34.801 |
Net Income After Taxes | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Net Income Before Extra. Items | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Net Income | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Income Available to Common Excl. Extra. Items | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Income Available to Common Incl. Extra. Items | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Diluted Net Income | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Diluted Weighted Average Shares | 8.7036 | 6.902 | 6.47781 | 5.769 | 5.3622 |
Diluted EPS Excluding Extraordinary Items | -1.31532 | -2.43784 | -2.88832 | -4.61692 | -6.49043 |
Diluted Normalized EPS | -1.31532 | -2.17161 | -2.62603 | -4.60982 | -6.49092 |
Other, Net | 0.025 | 0.006 | 2.06 | 0 | -0.012 |
Total Extraordinary Items | 0 | ||||
Depreciation / Amortization | 0.142 | 0.041 | 1.142 | ||
Unusual Expense (Income) | 0 | 2.808 | 2.727 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 0.131 | 0.077 | 0 | 1.5 | 0 |
Revenue | 0.131 | 0.077 | 1.5 | ||
Cost of Revenue, Total | |||||
Gross Profit | |||||
Total Operating Expense | 3.49 | 3.431 | 3.239 | 3.413 | 3.5 |
Selling/General/Admin. Expenses, Total | 2.22 | 2.185 | 2.205 | 2.265 | 2.569 |
Research & Development | 1.14 | 1.191 | 0.984 | 1.102 | 0.894 |
Depreciation / Amortization | 0.13 | 0.055 | 0.05 | 0.046 | 0.037 |
Unusual Expense (Income) | 0 | ||||
Operating Income | -3.359 | -3.354 | -3.239 | -1.913 | -3.5 |
Interest Income (Expense), Net Non-Operating | 0.095 | 0.033 | 0.026 | 0.002 | 0.002 |
Gain (Loss) on Sale of Assets | 0 | 0 | |||
Other, Net | 0 | 0 | 0 | 0 | 0 |
Net Income Before Taxes | -3.264 | -3.321 | -3.213 | -1.911 | -3.498 |
Net Income After Taxes | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Net Income Before Extra. Items | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Net Income | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Income Available to Common Excl. Extra. Items | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Income Available to Common Incl. Extra. Items | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Diluted Net Income | -3.264 | -3.321 | -3.215 | -1.911 | -3.5 |
Diluted Weighted Average Shares | 8.71362 | 8.71228 | 8.71097 | 8.70551 | 8.7055 |
Diluted EPS Excluding Extraordinary Items | -0.37459 | -0.38119 | -0.36907 | -0.21952 | -0.40204 |
Diluted Normalized EPS | -0.37459 | -0.38119 | -0.36907 | -0.21952 | -0.40204 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 29.533 | 38.398 | 28.318 | 38.574 | 46.76 |
Cash and Short Term Investments | 28.675 | 37.364 | 27.356 | 36.477 | 43.726 |
Cash & Equivalents | 28.675 | 37.364 | 27.356 | 36.477 | 43.726 |
Total Receivables, Net | 0 | 0.111 | 0.558 | 1.028 | |
Accounts Receivable - Trade, Net | 0 | 0.111 | 0.503 | 0.883 | |
Total Inventory | 0 | 0.49 | 0.842 | ||
Prepaid Expenses | 0.858 | 1.034 | 0.851 | 1.049 | 1.164 |
Total Assets | 33.296 | 39.917 | 28.441 | 40.623 | 49.827 |
Property/Plant/Equipment, Total - Net | 2.815 | 0.381 | 0 | 1.832 | 2.788 |
Property/Plant/Equipment, Total - Gross | 3.886 | 1.383 | 0.415 | 6.413 | 6.856 |
Accumulated Depreciation, Total | -1.071 | -1.002 | -0.415 | -4.581 | -4.068 |
Intangibles, Net | 0.094 | 0.109 | 0.123 | 0.137 | 0.151 |
Other Long Term Assets, Total | 0.854 | 1.029 | 0 | 0.08 | 0.128 |
Total Current Liabilities | 1.383 | 0.721 | 1.81 | 3.737 | 4.658 |
Accounts Payable | 0.415 | 0.281 | 0.72 | 0.628 | 0.464 |
Accrued Expenses | 0.968 | 0.44 | 1.09 | 2.584 | 3.526 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.525 | 0.668 | ||
Total Liabilities | 3.087 | 0.721 | 1.81 | 4.325 | 5.241 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 1.704 | 0 | 0.588 | 0.583 | |
Total Equity | 30.209 | 39.196 | 26.631 | 36.298 | 44.586 |
Common Stock | 0.009 | 0.009 | 0.131 | 0.124 | 0.111 |
Additional Paid-In Capital | 337.94 | 335.479 | 305.965 | 296.929 | 278.595 |
Retained Earnings (Accumulated Deficit) | -307.739 | -296.291 | -279.465 | -260.755 | -234.12 |
Other Equity, Total | 0 | ||||
Total Liabilities & Shareholders’ Equity | 33.296 | 39.917 | 28.441 | 40.623 | 49.827 |
Total Common Shares Outstanding | 8.71063 | 8.67049 | 6.52791 | 6.20077 | 5.55165 |
Treasury Stock - Common | -0.001 | -0.001 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 29.533 | 31.171 | 34.303 | 36.658 | 38.398 |
Cash and Short Term Investments | 28.675 | 30.269 | 33.791 | 36.008 | 37.364 |
Cash & Equivalents | 28.675 | 30.269 | 33.791 | 36.008 | 37.364 |
Total Receivables, Net | 0 | ||||
Accounts Receivable - Trade, Net | 0 | ||||
Prepaid Expenses | 0.858 | 0.902 | 0.512 | 0.65 | 1.034 |
Total Assets | 33.296 | 35.095 | 35.881 | 38.294 | 39.917 |
Property/Plant/Equipment, Total - Net | 2.815 | 2.921 | 0.552 | 0.554 | 0.381 |
Other Long Term Assets, Total | 0.948 | 1.003 | 1.026 | 1.082 | 1.138 |
Total Current Liabilities | 1.383 | 2.006 | 1.675 | 0.964 | 0.721 |
Accounts Payable | 0.415 | 0.605 | 0.958 | 0.577 | 0.281 |
Accrued Expenses | 0.968 | 1.401 | 0.717 | 0.387 | 0.44 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.087 | 3.802 | 1.675 | 0.964 | 0.721 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 30.209 | 31.293 | 34.206 | 37.33 | 39.196 |
Common Stock | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
Additional Paid-In Capital | 337.94 | 337.113 | 336.526 | 336.145 | 335.479 |
Retained Earnings (Accumulated Deficit) | -307.739 | -305.828 | -302.328 | -298.823 | -296.291 |
Treasury Stock - Common | -0.001 | -0.001 | -0.001 | -0.001 | -0.001 |
Total Liabilities & Shareholders’ Equity | 33.296 | 35.095 | 35.881 | 38.294 | 39.917 |
Total Common Shares Outstanding | 8.71063 | 8.70555 | 8.70545 | 8.69813 | 8.67049 |
Other Liabilities, Total | 1.704 | 1.796 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.448 | -16.826 | -18.71 | -26.635 | -34.803 |
Cash From Operating Activities | -8.453 | -13.323 | -14.882 | -20.375 | -28.857 |
Cash From Operating Activities | 0.142 | 0.041 | 1.142 | 0.98 | 1.267 |
Non-Cash Items | 2.256 | 5.575 | 3.684 | 5.13 | 6.767 |
Cash Taxes Paid | 0.002 | -0.002 | -0.002 | -0.003 | 0.002 |
Changes in Working Capital | 0.597 | -2.113 | -0.998 | 0.15 | -2.088 |
Cash From Investing Activities | -0.409 | -0.393 | 0.747 | -0.076 | -0.292 |
Capital Expenditures | -0.409 | -0.405 | 0 | -0.079 | -0.296 |
Other Investing Cash Flow Items, Total | 0 | 0.012 | 0.747 | 0.003 | 0.004 |
Cash From Financing Activities | 0.205 | 23.835 | 4.935 | 13.154 | 10.113 |
Issuance (Retirement) of Stock, Net | 0.251 | 23.839 | 4.996 | 13.377 | 10.113 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Foreign Exchange Effects | 0 | 0.011 | |||
Net Change in Cash | -8.657 | 10.119 | -9.2 | -7.297 | -19.025 |
Financing Cash Flow Items | -0.046 | -0.004 | -0.061 | -0.223 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.8 | -6.536 | -3.215 | -11.448 | -9.537 |
Cash From Operating Activities | -7.675 | -4.631 | -2.414 | -8.453 | -6.912 |
Cash From Operating Activities | 0.234 | 0.104 | 0.05 | 0.142 | 0.096 |
Non-Cash Items | 1.896 | 1.346 | 0.655 | 2.256 | 1.429 |
Cash Taxes Paid | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Changes in Working Capital | -0.005 | 0.455 | 0.096 | 0.597 | 1.1 |
Cash From Investing Activities | -0.804 | -10.779 | -10.693 | -0.409 | -0.356 |
Capital Expenditures | -0.234 | -0.193 | -0.074 | -0.409 | -0.356 |
Other Investing Cash Flow Items, Total | -0.57 | -10.586 | -10.619 | 0 | 0 |
Cash From Financing Activities | 0 | 0 | 0 | 0.205 | 0.205 |
Financing Cash Flow Items | 0 | 0 | -0.046 | -0.046 | |
Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0.251 | 0.251 |
Net Change in Cash | -8.479 | -15.41 | -13.107 | -8.657 | -7.063 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 5.2183 | 454752 | -6624 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.25 | 283225 | 151 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 2.4591 | 214302 | -60565 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.691 | 147360 | -185 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.2859 | 112057 | -7830 | 2022-12-31 | HIGH |
Murphy (Keith E) | Individual Investor | 1.0721 | 93427 | 19607 | 2022-11-10 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7418 | 64641 | -151 | 2022-12-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.5815 | 50672 | 369 | 2022-12-31 | MED |
Cohen (Douglas Jay) | Individual Investor | 0.3627 | 31607 | 19607 | 2022-11-10 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3194 | 27831 | 0 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.3111 | 27113 | 10 | 2022-12-31 | MED |
Stern (Adam K.) | Individual Investor | 0.225 | 19607 | 19607 | 2022-11-10 | HIGH |
Joshi (Vaidehi) | Individual Investor | 0.225 | 19607 | 19607 | 2022-11-10 | |
Milhous (Alison Tjosvold) | Individual Investor | 0.225 | 19607 | 19607 | 2022-11-10 | |
Gobel (David) | Individual Investor | 0.225 | 19607 | 19607 | 2022-11-10 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1659 | 14461 | 0 | 2022-12-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0753 | 6559 | -182 | 2022-12-31 | LOW |
CGM-AZIMUT MONACO | Investment Advisor | 0.0631 | 5500 | 0 | 2023-01-31 | MED |
UBS Financial Services, Inc. | Investment Advisor | 0.0482 | 4202 | -2041 | 2022-12-31 | LOW |
Advisor Group, Inc | Investment Advisor | 0.0319 | 2783 | -224 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Organovo Holdings, Inc. Company profile
About Organovo Holdings Inc
Organovo Holdings, Inc. is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.
Financial summary
BRIEF: For the nine months ended 31 December 2021, Organovo Holdings Inc revenues was not reported. Net loss decreased 33% to $9.5M. Lower net loss reflects Non-cash stock-based compensation decrease of 78% to $1.2M (expense), Gain (loss) on fixed asset disposals decrease from $19K (expense) to $0K, Other income increase from $6K to $25K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.15 to -$1.10.
Equity composition
Common Stock $.0001 Par, 06/12 Shares auth.75M and o/s 43,772,483. Insiders 39.83%. 02/12, 10.59135-for-1 Stock split.
Industry: | Biotechnology & Medical Research (NEC) |
Suite 110
6275 Nancy Ridge Drive
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com